Can Targeting Nucleotide Biosynthesis Be a Therapeutic Strategy?
Yes, targeting nucleotide biosynthesis has been a viable therapeutic strategy in cancer treatment. Drugs that inhibit key enzymes in both the de novo and salvage pathways are already in clinical use. For example, methotrexate inhibits dihydrofolate reductase, while 5-fluorouracil targets thymidylate synthase. Novel inhibitors and combinatory approaches are currently under investigation to improve efficacy and reduce resistance.
